Antidepressant Response Prediction Using Genetic Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting antidepressant treatment for depression are often trial-and-error, leading to prolonged treatment times and high rates of adverse side effects due to the variability in patient response, which is influenced by both clinical and genetic factors, necessitating a more predictive approach.
Innovation Solution
A method that combines clinical and genetic data, specifically using polymorphic sites such as rs17291388, rs558025, and rs7201082, along with clinical features like treatment history and symptom severity, to predict the efficacy and side effects of antidepressants like citalopram and venlafaxine through a classification algorithm, enabling personalized treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If trial-and-error methods are used to select antidepressant treatment, then treatment options can be explored, but treatment time is prolonged and adverse side effects increase
Solution Approach 1:
The patent performs genetic testing and classification algorithm analysis before antidepressant treatment begins, determining treatment response likelihood in advance. This preliminary action identifies suitable medications upfront, avoiding the trial-and-error process and reducing the time to optimal treatment while maintaining high prediction accuracy through validated genetic markers.
2Reliability
If trial-and-error methods are used to select antidepressant treatment, then treatment options can be explored, but adverse side effects increase
Solution Approach 1:
The patent applies preliminary anti-action by predicting adverse side effects before treatment begins using genetic classification. The system identifies patients at high risk for specific side effects based on their genetic profile, allowing clinicians to select alternative medications that avoid these harmful effects while maintaining therapeutic efficacy.
3Measurement precision
If multiple gene variants are analyzed to explain treatment variance, then prediction accuracy may improve, but system complexity increases
Solution Approach 1:
The patent extracts and focuses on specific, high-impact genetic variants and polymorphic sites that have been validated to strongly predict antidepressant response. Rather than analyzing all possible genetic variants, the system identifies and measures only the most relevant markers, reducing analytical complexity while maintaining high prediction accuracy through targeted genetic assessment.
Data Source
AI summary
Methods for predicting antidepressant treatment response for a subject in need thereof, for predicting resistance to antidepressant treatment, and for generating a predictor of response to antidepressant treatment, are provided.